TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Caregiver health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Response of rectal cancer organoids to irradiation and chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in baseline heart rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distal upper limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate for treated and untreated lips
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration required to elicit a positive response after nasal provocation test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with CD4 counts < 500 cells/microliter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neurological improvement on ASIA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Free From Major Adverse Events at 30 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Primary Patency at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma AUC of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Menstrual pain score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of serum with anti GBM positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effect of salbutamol administration on ANS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolapse assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Severity Rating (CSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment gains and overall patient functioning
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: development of AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in CD137 positive NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Drop in regional oxygen saturation (rSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patch adhesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Relief of provoked pain associated with sunburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in peak oxygen consumption (MVO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of ocular and non-ocular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Quantification of gene expression of cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean change in blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: GMA term age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps muscle strength (MVIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Relative perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of male clients aged 20-34 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary lesion severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Healing of ischemic foot ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease control rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sexual Bother score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Urinary Bother score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progression Free Survival-6m rate
Endpoint domain: Mortality/survival
Primary endpoint: serum B12 status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum folate status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Antibody levels for meningococcal serogroups A & C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bactericidal titers for meningococcal serogroups A & C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody levels for DTP booster vaccine antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in estimated glomerular filtration Rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sinonasal symptoms (SNOT-20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in 100mmVAS score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Curve Zero to Infinity (AUC[0-∞]) for LY3314814
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK Profile for Simvastatin: AUC(0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK Profile for Midazolam: AUC(0-∞) Oral and IV Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PK Profile for Donepezil: AUC(0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: infections rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: muscle biopsy sample (musculus multifidus)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: quantitative tissue displacement and strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: timing of change in the relative myoelectric activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: strain ratio in the context of motions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in epigenetic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Vascular Event
Endpoint domain: Mortality/survival
Primary endpoint: Confusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Curve of Serum LNG Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve of Serum UPA Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of GCC-4401C
Endpoint domain: Adverse events/effects
Primary endpoint: Number of solicited local adverse events related to product
Endpoint domain: Adverse events/effects
Primary endpoint: Number of serious adverse events from day 0 through 28 days after the last dose
Endpoint domain: Adverse events/effects
Primary endpoint: Number of potential immune-mediated diseases from Day 0 through 28 days after the last dose
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with clinically relevant changes in vital parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Donor Specific Antibodies (DSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Persistence of Study Drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net and gross sick-leave days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Contraceptive effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response Rate in Hemoglobin (HGB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sustained Virological Response (SVR) at 12 Weeks After End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in base plate wear time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure rehospitalisation rate
Endpoint domain: Mortality/survival
Primary endpoint: Combined endpoint death or heart failure rehospitalisation
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of catheter associated urinary tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: Skeletal muscle PCr on-kinetic during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carnitine acetyltransferase (CrAT) protein content/activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve for serum Pegfilgrastim
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of molecular remissions (MRD < 10(-4))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission duration/survival
Endpoint domain: Mortality/survival
Primary endpoint: response (CR/PR/MR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total plasma triacylglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chylomicron triacylglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of Residual Platelet Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall Lens Handling
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants with Infectious Endocarditis
Endpoint domain: Adverse events/effects
Primary endpoint: Usefulness of new staining method
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Fabry disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of daily footsteps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General Well Being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Detection rate of polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Variability in plasma levodopa concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Energy delivered for lens nucleus aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: phospholipase A2 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Percent Hemoglobin (HbA) Decrement Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean monthly number of headache days with moderate or severe intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional gain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clinical response at week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Clinical Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Cumulative Skin Irritation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Subjects with Skin sensitization potential
Endpoint domain: Adverse events/effects
Primary endpoint: modified Vancouver Scar Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Bacterial Reduction on the Abdomen and Groin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour urinary protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of subjects with COVID-19 disease progression
Endpoint domain: Mortality/survival
Primary endpoint: Total number of days alive and out of hospital
Endpoint domain: Mortality/survival
Primary endpoint: Change in volume status (intracellular, extracellular volume, and total body water)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUC(0-inf) Lu AG06466
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf) Lu AG06988
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax Lu AG06466
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax Lu AG06988
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Eligible Dyads (Parent-child) Who Enroll
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percent of Participants With Treatment Specific Retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of Participants Who Completed At-home Practices
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Score on Caregiver/Children Reports of Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Total Weekly Walking Minutes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Absolute Change in the Proportion of Subjects Diagnosed With SND
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in the Proportion of Subjects Receiving Indicated Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total drainage volume after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of mature oocytes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: 28-day ICU mortality
Endpoint domain: Mortality/survival
Primary endpoint: biochemical Progression Free Survival (bPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Temperature difference between burned zone and healthy zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental plaque microbiota profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of application of action ETP
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients initiating midostaurin treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Handicap in everyday life
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: MRSI glutamate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endoscopic laryngeal examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve of DOTAREM in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate Constant of the Terminal Phase of DOTAREM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Elimination Half-life of DOTAREM From Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in 24-hour Blood Pressure at Months 6 and 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in CPAP Adherence by Active Treatment Arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodic Blood Pressure Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral Blood Flow Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Continues Blood Pressure Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Employment Outcomes Survey
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of Participants Achieving Spleen Volume Reduction (SVR) ≥35%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient survival rate at 6 months
Endpoint domain: Mortality/survival
Primary endpoint: Quality of life at 4 months (mobility)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of life at 4 months (worries about the future)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life at 4 months (illness burden)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: scar erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: scar blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of complete radiologic response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration Levels of IL-1 Receptor Antagonist (IL-1ra)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Presence of LN bacteria strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change of serum glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of the meningococcal C vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: serum levels of gamma tocopherol and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of physical pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean mitral valve gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Thickness, surface and branching vessels of the retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Abatacept Trough Concentration (Cmin)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monitoring respiratory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean change in visual field area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decrease in number of epistaxis episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Stability Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in somatosensory evoked potentials signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Differences in motor evoked potentials signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the concentration-time curve of repaglinide in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of repaglinide in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of total bupropion in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of S-bupropion in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of total bupropion in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes of Use Per Night at Month 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes of Use Per Night at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Minutes of Use Per Night From Month 1 to Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary vascular permeability index (PVPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient satisfaction with intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Technical difficulties
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in dose of oral corticosteroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection of infections
Endpoint domain: Adverse events/effects
Primary endpoint: Short Physical Performance Battery (SPBB)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Primary effective endpoint
Endpoint domain: Physiological/clinical
Primary endpoint: Change in Cohen-Mansfield Agitation Inventory (CMAI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of assessments
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Migraine Impact and Disability
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mass Balance Recovery of Total Radioactivity in Urine and Faeces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes